Controversial aspects of hormone replacement therapy upon cardiovascular mortality and morbidity of women in menopause.
Rosano
G M
GM
Mercuro
G
G
D000367:Age Factors; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003327:Coronary Disease / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D003627:Data Interpretation, Statistical; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008055:Lipids / Q000097:blood; D008297:Male; D008593:Menopause; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D005082:Physical Exertion; D010919:Placebos; D017698:Postmenopause; D011372:Progestins / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D012959:Socioeconomic Factors; D013997:Time Factors
D000924:Anticholesteremic Agents; D004967:Estrogens; D008055:Lipids; D010919:Placebos; D011372:Progestins